Skip to main content
. 2021 Nov 17;29(4):501–507. doi: 10.1016/j.acra.2021.11.010

Table 2.

Number of Patients with Resolved Subclinical LAD, Unresolved Subclinical LAD, and Lost to Follow-Up After 6-8 Weeks from Initial Screen/Diagnostic

No vaccine Moderna Pfizer Total
LAD resolved on imaging follow-up - returned to previous screening schedule (BIRADS 2) 6 12 11 29
LAD not resolved - recommended continued imaging follow-up (presently BIRADS 3) 3 2 4 9
Lost to follow-up 0 1 4 5